amedica is the only manufacturer of medical grade silicon nitride, an innovative biomaterial technology ideal for use in spinal fusion and across a variety of medical applications. our silicon nitride features a unique nanosurface texture that promotes bone growth and addresses clinical needs by providing excellent imaging capabilities and demonstrating antibacterial characteristics. our interbody fusion devices and pedicle screw systems are designed to benefit both the patient and the surgeon. with the only fda registered and iso 1345 certified silicon nitride medical device manufacturing facility in the world and a strong sales and distribution organization, we are committed to providing innovative healthcare solutions that improve patient quality of life.
Company profile
Ticker
SINT
Exchange
Website
CEO
B. Sonny Bal
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMEDICA CORP, AMEDICA Corp
SEC CIK
Corporate docs
Subsidiaries
SINTX Armor, Inc. • Technology Assessment and Transfer, Inc. ...
SINT stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
27 Mar 24
8-K
SINTX Technologies Announces Proposed Public Offering of Common Stock
26 Mar 24
424B5
Prospectus supplement for primary offering
26 Mar 24
424B5
Prospectus supplement for primary offering
22 Mar 24
424B5
Prospectus supplement for primary offering
22 Mar 24
8-K
Other Events
14 Feb 24
8-K
Sintx Technologies Announces Pricing of $4.0 Million Public Offering
2 Feb 24
424B4
Prospectus supplement with pricing info
1 Feb 24
EFFECT
Notice of effectiveness
1 Feb 24
8-K
Other Events
31 Jan 24
Transcripts
Latest ownership filings
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G
Lind Global Fund II LP
7 Feb 24
SC 13G
INTRACOASTAL CAPITAL, LLC
16 Feb 23
SC 13G
Lind Global Fund II LP
14 Feb 23
4
David W. Truetzel
14 Dec 22
SC 13G/A
Kershner Trading Americas,LLC
24 Feb 21
SC 13G
Kershner Trading Americas,LLC
5 Feb 21
SC 13G/A
ALPHA CAPITAL ANSTALT
14 Jan 21
4
David Francis O'Brien
1 Sep 20
3
David Francis O'Brien
1 Sep 20
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.22 mm | 6.22 mm | 6.22 mm | 6.22 mm | 6.22 mm | 6.22 mm |
Cash burn (monthly) | 1.04 mm | (no burn) | 1.20 mm | 1.22 mm | 972.00 k | 1.09 mm |
Cash used (since last report) | 6.16 mm | n/a | 7.16 mm | 7.23 mm | 5.78 mm | 6.48 mm |
Cash remaining | 57.67 k | n/a | -943.12 k | -1.01 mm | 440.15 k | -256.44 k |
Runway (months of cash) | 0.1 | n/a | -0.8 | -0.8 | 0.5 | -0.2 |
Institutional ownership, Q2 2023
27.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 17 |
Opened positions | 3 |
Closed positions | 8 |
Increased positions | 4 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 109.05 mm |
Total shares | 1.48 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Kershner Trading Americas,LLC | 970.34 k | $2.73 mm |
Lind Global Fund II | 257.50 k | $700.00 k |
Intracoastal Capital | 119.60 k | $738.00 k |
Vanguard | 38.43 k | $47.26 mm |
Renaissance Technologies | 29.64 k | $36.00 k |
Citadel Advisors | 22.01 k | $27.52 mm |
STT State Street | 17.29 k | $21.62 mm |
Alpha Capital Anstalt | 16.46 k | $26.00 k |
Tower Research Capital | 3.32 k | $4.08 mm |
MS Morgan Stanley | 2.23 k | $2.74 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Nov 22 | David W. Truetzel | Common stock | Sell | Dispose S | Yes | No | 0.1239 | 67 | 8.30 | 4 |
News
Nasdaq Turns Higher; Akanda Shares Plunge
25 Mar 24
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
12 Health Care Stocks Moving In Monday's Intraday Session
25 Mar 24
Crude Oil Moves Higher; US New Home Sales Fall In February
25 Mar 24
Why SINTX Technologies Stock Is Down 50%
25 Mar 24
Press releases
SINTX Technologies Announces Proposed Public Offering of Common Stock
22 Mar 24
SINTX Technologies Announces Closing of $4.0 Million Public Offering
2 Feb 24
SINTX Technologies Announces Pricing of $4.0 Million Public Offering
31 Jan 24
SINTX SUBSIDIARY TECHNOLOGY ASSESSMENT & TRANSFER TO DEVELOP 3D PRINTING AND CMCs WITH DEVCOM-ARMY RESEARCH LABORATORY
30 Jan 24